Disparities in Cancer Care for Minority Populations

Disparities in Cancer Care for Minority Populations

Identifying and Correcting Disparities: The Importance of Participation by Non-Oncologists

Not a member of My prIME? Join now for instant access.

Meeting Overview

This interactive symposium is designed to provide non-oncologists the opportunity to interact with and learn from experts in cancer medicine. These thought leaders will provide a broad overview of current treatment principles, along with key outstanding challenges related to disparities in oncology.

This presentation was selected by the National Medical Association (NMA) as an independent educational activity held in conjunction with the NMA Annual Convention & Scientific Assembly. The presentation’s content and the views expressed therein are those of the presenters and not of NMA.

Date and Location

Tuesday, August 1, 2017
7.00 AM – 9.00 AM

Internal Medicine Room – 201 AB
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, Pennsylvania 19107



Tuesday, August 1, 2017
7.00 AM – 9.00 AM



Philadelphia, Pennsylvania, United States



2.0 AMA PRA Category 1 Credits™

7.00 AM Welcome and introduction
Edith P. Mitchell, MD, FACP, FCPP
7.05 AM Are you an Oncology Guru™?
Edith P. Mitchell, MD, FACP, FCPP
7.15 AM Prostate cancer
Arthur L. Burnett, MD, MBA, FACS
7.35 AM Q & A and faculty discussion
7.40 AM Breast cancer
Lisa A. Newman, MD, MPH, FACS, FASCO
8.00 AM Q & A and faculty discussion
8.05 AM Cervical cancer
Carol L. Brown, MD, FACOG, FACS
8.25 AM Q & A and faculty discussion
8.30 AM Lynch syndrome
Michael J. Hall, MD, MS
8.50 AM Q & A and faculty discussion
8.55 AM prIME PointsTM
Edith P. Mitchell, MD, FACP, FCPP
9.00 AM Adjourn


  • Edith P. Mitchell, MD, FACP, FCPPThomas Jefferson University
    Philadelphia, Pennsylvania, United States

  • Carol L. Brown, MD, FACOG, FACSMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Arthur L. Burnett, MD, MBA, FACSJohns Hopkins Medicine
    Baltimore, Maryland, United States
  • Michael J. Hall, MD, MSFox Chase Cancer Center
    Philadelphia, Pennsylvania, United States
  • Lisa A. Newman, MD, MPH, FACS, FASCOHenry Ford Health System
    Detroit, Michigan, United States

This educational activity is specifically designed to meet the needs of internists, general practitioners, surgeons, obstetricians/gynecologists, urologists, gastroenterologists, and other healthcare providers.

After successful completion of this educational activity, participants should be able to:

  • Employ current evidence-based best practices regarding the utilization of diagnostic tools for patients with prostate cancer
  • Assess the implications of disparities on the diagnosis of patients with breast cancer and utilize strategies to overcome these disparities to improve outcomes
  • Integrate recent data regarding the potential influence of racial disparities on the diagnosis and, ultimately, clinical outcomes of patients with cervical cancer
  • Evaluate the implications of disparities on screening and diagnosis for patients with Lynch syndrome

This educational activity is supported by grants from Astellas; Lilly USA, LLC; and Merck and Co, Inc.







Cobb institute

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA Disclosure Statement

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.